Intellia Therapeutics (NTLA) PT Lowered to $9 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Luca Issi lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $9.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
